Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

353

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Diabetes Mellitus
Interventions
DRUG

Rosuvastatin

10 mg oral dose administered once daily for 52 weeks

DRUG

Rosuvastatin

20 mg oral dose administered once daily for 4 weeks followed by 40 mg oral dose administered once daily for 48 weeks

DRUG

Atorvastatin

40 mg oral dose administered once daily for 4 weeks followed by 80 mg oral dose administered once daily for 48 weeks

Trial Locations (116)

Unknown

Research Site, Avondale

Research Site, Phoenix

Research Site, Jonesboro

Research Site, Pasadena

Research Site, Riverside

Research Site, Santa Ana

Research Site, West Hills

Research Site, Hollywood

Research Site, Jacksonville

Research Site, West Palm Beach

Research Site, Augusta

Research Site, Topeka

Research Site, Springfield

Research Site, Detroit

Research Site, Columbia

Research Site, St Louis

Research Site, Orchard Park

Research Site, Stony Brook

Research Site, Winston-Salem

Research Site, Cincinnati

Research Site, Kettering

Research Site, Pittsburgh

Research Site, Columbia

Research Site, Dallas

Research Site, Houston

Research Site, Lubbock

Research Site, San Antonio

Research Site, Ogden

Research Site, Milwaukee

Research Site, Buenos Aires

Reasearch Site, La Plata

Research Site, Morón

Research Site, Quilmes

Research Site, Curitiba

Research Site, Fortaleza

Research Site, Goiânia

Research Site, Recife

Research Site, São Paulo

Research Site, Burgas

Research Site, Gabrovo

Research Site, Pleven

Research Site, Plovdiv

Research Site, Sofia

Research Site, Varna

Research Site, Veliko Tarnovo

Research Site, Vancouver

Research Site, Courtice

Research Site, North York

Research Site, Oshawa

Research Site, Ottawa

Research Site, Richmond Hill

Research Site, Scarborough Village

Research Site, Thunder Bay

Research Site, Greenfield Park

Research Site, Montreal

Research Site, Aalborg

Research Site, Blegdamsvej 9

Research Site, Farsø

Research Site, Gentofte Municipality

Research Site, Hillerød

Research Site, Hvidovre

Research Site, Køge

Research Site, Annonay

Research Site, Besançon

Research Site, Bondy

Research Site, Colmar

Research Site, Corbeil-Essonnes

Research Site, Corsept

Research Site, Creil

Research Site, Grenoble

Research Site, La Chapelle-sur-Erdre

Research Site, Nantes

Research Site, Paris

Research Site, Pessac

Research Site, Quimper

Research Site, Baja

Research Site, Balatonfüred

Research site, Budapest

Research Site, Debrecen

Research Site, Győr

Research site, Gyula

Research Site, Hodmeztvasarhely

Research Site, Kecskemét

Research Site, Keszthely

Research Site, Miskolc

Research Site, Mosonmagyaróvár

Research Site, Nyíregyháza

Research Site, Székesfehérvár

Research Site, Szolnok

Research Site, Tatabánya

Research Site, Zalaegerszeg

Research Site, Acireale

Research Site, Florence

Research Site, Roma

Research Site, Sottomarnia Di Chioggia

Research Site, Bergamo

Research Site, Cagliari

Research Site, Milan

Research Site, San Giovanni Rotondo

Research Site, Sassari

Research Site, Treviglio

Research Site, Aguascalientes

Research Site, Cauntla

Research Site, Distrito Federal

Research Site, Durango

Research Site, Guadalajara

Research Site, Saltillo

Research Site, San Luis Potosí City

Research Site, Zapopan

Research Site, Baia Mare

Research Site, Brasov

Research Site, Bucharest

Research Site, Craiova

Research Site, Lasi

Research Site, Târgu Mureş

Research Site, Timișoara

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY

NCT00296374 - Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal Disease | Biotech Hunter | Biotech Hunter